ABSTRACT
The management of most autoimmune rheumatic diseases (ARDs) has improved with major advances in drug development and our understanding of disease pathogenesis. ARDs share some clinical and serological characteristics and there is considerable overlap of immunosuppressive drugs used in their treatment. The overall goals in the management of these often complex conditions are reducing autoimmunity, suppressing inflammation, arresting disease progression, and achieving remission.
